Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022

MMWR Morb Mortal Wkly Rep. 2022 Feb 25;71(8):285-289. doi: 10.15585/mmwr.mm7108a1.

Abstract

On May 5, 2021, CDC's Tuberculosis Trials Consortium and the National Institutes of Health (NIH)-sponsored AIDS Clinical Trials Group (ACTG) published results from a randomized controlled trial indicating that a 4-month regimen containing rifapentine (RPT), moxifloxacin (MOX), isoniazid (INH), and pyrazinamide (PZA) was as effective as the standard 6-month regimen for tuberculosis (TB) treatment (1). On the basis of these findings, CDC recommends the 4-month regimen as a treatment option for U.S. patients aged ≥12 years with drug-susceptible pulmonary TB and provides implementation considerations for this treatment regimen.

Publication types

  • Practice Guideline

MeSH terms

  • Antitubercular Agents / administration & dosage
  • Antitubercular Agents / therapeutic use*
  • Centers for Disease Control and Prevention, U.S.
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Humans
  • Isoniazid / administration & dosage
  • Isoniazid / therapeutic use*
  • Moxifloxacin / administration & dosage
  • Moxifloxacin / therapeutic use*
  • Pyrazinamide / administration & dosage
  • Pyrazinamide / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Rifampin / administration & dosage
  • Rifampin / analogs & derivatives*
  • Rifampin / therapeutic use
  • Tuberculosis, Pulmonary / drug therapy*
  • United States

Substances

  • Antitubercular Agents
  • Pyrazinamide
  • Moxifloxacin
  • Isoniazid
  • Rifampin
  • rifapentine